SRC and cancer: Taken together, our results show for the first time amoeboid motility related to SRC‐mediated activation of the Rho/ROCK/pMLCII pathway via the RASSF1C oncogene, in cancer cells where the tumor suppressor RASSF1A is epigenetically silenced (schematic model, Fig 6D).